ÐÇ¿ÕÊÓÆµ

Novo Nordisk ÐÇ¿ÕÊÓÆµ membership restored

Novo Nordisk’s two-year suspension from the Association of the British Pharmaceutical Industry (ÐÇ¿ÕÊÓÆµ) for serious breaches of the ÐÇ¿ÕÊÓÆµ Code of Practice has come to an end [1].

Novo Nordisk’s return to full membership of the ÐÇ¿ÕÊÓÆµ follows extensive audits of Novo Nordisk’s compliance procedures and governance by the Prescription Medicines Code of Practice Authority (PMCPA). Specifics of the original case are available on the [2].

Novo Nordisk, supported by the independent PMCPA audit reports, has demonstrated to the ÐÇ¿ÕÊÓÆµ Board’s satisfaction that the company has made clear, significant, and sustained improvements to ensure it is able to properly adhere to the strict industry standards in the ÐÇ¿ÕÊÓÆµ Code of Practice.

Richard Torbett, Chief Executive of the ÐÇ¿ÕÊÓÆµ, said: “The UK rightly has some of the highest standards in the world for how pharmaceutical companies can behave and operate – embodied by the ÐÇ¿ÕÊÓÆµ Code of Practice. In 2021, Novo Nordisk fell short of these standards, and it is right that their peers held them accountable.

“Over the past two years, Novo Nordisk has responded positively and actively to the requirements laid down by the ÐÇ¿ÕÊÓÆµ Board, and I am pleased to welcome them back into full engagement as ÐÇ¿ÕÊÓÆµ members.â€

Sebnem Avsar Tuna, General Manager of Novo Nordisk UK said: “We welcome the decision today to have our membership to the ÐÇ¿ÕÊÓÆµ restored. Throughout the audit process we have considerably strengthened our compliance processes and we firmly believe that we now have the right foundations and governance in place to be fully and effectively self-regulating.

“From day one, we have taken the decision to suspend our membership extremely seriously, and we have greatly valued the cooperation from the ÐÇ¿ÕÊÓÆµ and the PMCPA during what has been a very robust and thorough review process.

“Novo Nordisk has had a significant presence in the UK for more than fifty years and we remain committed to our purpose of driving change to defeat serious chronic diseases and look forward to participating as a full member of the ÐÇ¿ÕÊÓÆµâ€

TAGS
  • PMCPA
  • Regulatory

Last modified: 17 March 2025

Last reviewed: 17 March 2025

[1] ÐÇ¿ÕÊÓÆµ press release, Novo Nordisk is suspended from ÐÇ¿ÕÊÓÆµ membership, March 2023
[2] PMCPA, Case: AUTH/3525/6/21 - Complainant v Novo Nordisk, 22 June 2021

The ÐÇ¿ÕÊÓÆµ exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the ÐÇ¿ÕÊÓÆµ so patients can get new treatments faster and the ÐÇ¿ÕÊÓÆµ can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.